Abstract
Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding
rates and technical challenges associated with application of currently available
hemostatic powders. The aim of the current study was to assess performance of UI-EWD
for nonvariceal upper gastrointestinal bleeding (NVUGIB).
Patients and methods A total of 56 consecutive patients that received UI-EWD monotherapy for endoscopic
hemostasis due to NVUGIB were retrospectively reviewed. Main study outcomes were success
rates with immediate hemostasis and rebleeding within 30 days. Outcomes were analyzed
by reviewing patient medical records.
Results Etiologies of bleeding were: post-endoscopic therapy bleeding in 46 (82.1 %), peptic
ulcer in 8 (14.3 %), tumor in 1 (1.8 %), and other in 1 (1.8 %). UI-EWD was successfully
applied at bleeding site in all cases. The success rate of immediate hemostasis was
96.4 % (54/56), and the 30-day rebleeding rate among patients that achieved immediate
hemostasis was 3.7 % (2/54). No adverse event related to use of UI-EWD occurred.
Conclusion UI-EWD was found to have a high immediate hemostasis success rate in NVUGIB when
used as monotherapy and showed promising results in terms of preventing rebleeding.